BioRestorative Therapies, Inc.
BRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | 0.01 | -0.00 |
| FCF Yield | -75.09% | -89.95% | -63.43% | -65.19% |
| EV / EBITDA | -0.93 | -0.65 | -0.45 | 0.58 |
| Quality | ||||
| ROIC | -135.44% | -147.36% | -170.40% | -79.84% |
| Gross Margin | 93.00% | -13.67% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.92 | 0.62 | 0.45 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 49.59% | 46.89% | 15.87% | -29.27% |
| Free Cash Flow Growth | -26.29% | -4.60% | -87.80% | -71.09% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.07 | 0.07 | 0.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -14.49 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,109.53 | -368.78 | -468.73 | -50.73 |